A research agreement between IPSEN and AGV Discovery
![A research agreement between IPSEN and AGV Discovery](https://www.agv-discovery.com/wp-content/uploads/2021/12/imageblog2-370x250-1-original.jpg)
AGV Discovery has entered into a collaboration with the major pharmaceutical company IPSEN for the development of its ERK inhibitor candidates. MAPK pathway represents a promising target as one of the most commonly mutated oncogenic driver pathways in cancers with high unmet medical needs.